Xencor (XNCR) Net Income towards Common Stockholders (2013 - 2026)

Xencor's (XNCR) quarterly Net Income towards Common Stockholders came in at -$128.9 million in Q1 2026, down 164.95% year-on-year from $198.5 million in Q1 2025, and down 1838.01% on a QoQ basis from -$6.7 million in Q4 2025.

Xencor (XNCR) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends

Xencor (XNCR) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$128.9 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 164.95% year-over-year to -$128.9 million in Q1 2026; TTM through Mar 2026 was -$172.4 million, a 18.31% increase from a year earlier, with the FY2025 full-year figure at -$92.1 million, up 61.05% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$128.9 million, down from -$6.7 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for XNCR reached as high as $23.6 million in Q1 2022 and fell as low as -$128.9 million in Q1 2026.
  • Historically, Net Income towards Common Stockholders has averaged -$40.8 million across 5 years, with a median of -$34.0 million in 2022.
  • Across the five-year window, Net Income towards Common Stockholders jumped 1048.69% in 2022 and plunged 348.24% in 2023, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$12.0 million in 2022, then sank by 118.49% to -$26.3 million in 2023, then sank by 75.6% to -$46.2 million in 2024, then surged by 85.6% to -$6.7 million in 2025, then plunged by 1838.01% to -$128.9 million in 2026.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$128.9 million in Q1 2026, -$6.7 million in Q4 2025, and -$6.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -625.73
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -0.68
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -453.82 Mn
10 Xencor 1.49 Bn 1.11 Bn - -128.94 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -128.94 Mn
Dec 31, 2025 -6.65 Mn
Sep 30, 2025 -6.03 Mn
Jun 30, 2025 -30.83 Mn
Mar 31, 2025 -48.67 Mn
Dec 31, 2024 -46.20 Mn
Sep 30, 2024 -47.44 Mn
Jun 30, 2024 -68.78 Mn
Mar 31, 2024 -74.12 Mn
Dec 31, 2023 -26.31 Mn
Sep 30, 2023 -24.27 Mn
Jun 30, 2023 -71.11 Mn
Mar 31, 2023 -58.57 Mn
Dec 31, 2022 -12.04 Mn
Sep 30, 2022 -32.76 Mn
Jun 30, 2022 -33.98 Mn
Mar 31, 2022 23.59 Mn
Dec 31, 2021 73.06 Mn
Sep 30, 2021 -40.19 Mn
Jun 30, 2021 52.25 Mn